Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 374, Issue 9684, 2009, Pages 119-125

  Taha, Ali S ^a   McCloskey, Caroline ^a   Prasad, Rakesh ^a   Bezlyak, Vladimir ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALGINIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BISODOL; CLOPIDOGREL; DIPYRIDAMOLE; FAMOTIDINE; MAGALDRATE; PLACEBO; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLON POLYP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; DYSPEPSIA; FALLING; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEALTH CENTER; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SIDE EFFECT; STOMACH ULCER; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 67649861111     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61246-0     Document Type: Article

References (29)

1. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
2. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
3. Belch J., Macuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) 1030-1034
4. Taha A.S., Angerson W.J., Knill-Jones R.P., and Blatchford O. Clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin and antithrombotic drugs. Aliment Pharmacol Ther 24 (2006) 633-636
5. Taha A.S., Angerson W.J., Prasad R., McCloskey C., and Blatchford O. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 26 (2007) 1171-1178
6. Taha A.S., Angerson W.J., Prasad R., McCloskey C., Gilmour D., and Morran C.G. The incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 28 (2008) 878-885
7. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103 (2008) 2465-2473
8. Lanas A., Rodrigo L., Marquez J.L., et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDs and omeprazole. Scand J Gastroenterol 38 (2003) 693-700
9. Forgacs I., and Loganayagam A. Overprescribing proton pump inhibitors is expensive and not evidence based. BMJ 336 (2008) 2-3
10. Garcia Rodriguez L.A., Ruigomez A., and Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 5 (2007) 1418-1423
11. Sarkar M., Hennessy S., and Yang Y.X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149 (2008) 391-398
12. Targownik L.E., Lix L.M., Metge C.J., et al. Use of proton pump inhibitors and risk of osteoporosis related fractures. CMAJ 179 (2008) 319-326
13. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
14. Juurlink D.N., Gomes T., Ko D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 (2009) 713-738
15. Taha A.S., Sturrock R.D., and Russell R.I. Mucosal erosions in chronic NSAID users. Predisposition to ulceration and relationship to Helicobacter pylori. Gut 36 (1995) 334-336
16. Taha A.S., Angerson W.J., Knill-Jones R.P., and Blatchford O. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and anti-thrombotic drugs. Aliment Pharmacol Ther 23 (2006) 489-495
17. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996) 1435-1439
18. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for healing of and maintenance in nonsteroidal anti-inflammatory drugs-associated gastroduodenal ulceration. Gastroenterology 112 (1997) 1817-1822
19. Taha A.S., Dahill S., Morran C., et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology 116 (1999) 254-259
20. Yeomans N.D., and Naesdal J. Systematic review: ulcer definition in NSAID ulcer prevention trials. Aliment Pharmacol Ther 27 (2008) 465-472
21. Lanza F.L., Graham D.Y., Davis R.E., and Rack M.F. Endoscopic evaluation of cimetidine and sucralfate for prevention of naproxen-induced gastroduodenal injury: effects of scoring method. Dig Dis Sci 35 (1990) 1494-1499
22. Lundell L.R., Dent J., Bennett J.R., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
23. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
24. Laine L., Maller E.S., Yu C., Quan H., and Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127 (2004) 395-402
25. Niv Y., Battler A., Abuksis G., et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 50 (2005) 78-80
26. Lan K.K.G., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663
27. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
28. Daneshmend T.K., Prichard P.J., Bhaskar N.K., Millns P.J., and Hawkey C.J. Use of microbleeding and an ultrathin microscope to assess gastric mucosal protection by famotidine. Gastroenterology 97 (1989) 944-949
29. Chan F.K.L. Proton-pump inhibitors in peptic ulcer disease. Lancet 372 (2008) 1198-1200